A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Stopped early · Phase 1

Conditions studied: Renal Cell Carcinoma

In brief

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Key facts

Study ID

NCT01677390

Run by

Seagen Inc.

People needed

4

Starts

2012-08-01

Expected to finish

2013-12-01

Last updated by the study team

2014-01-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
• Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
• Measurable disease
• Eastern Cooperative Oncology Group performance status 0 or 1
• Adequate lung and renal function

You may not qualify if…

• Prior treatment with anti-CD70-directed therapy
• Received more than one prior treatment with an mTOR inhibitor

Where it is running

• Stanford Cancer Center — Stanford, California, United States
• Rocky Mountain Cancer Centers - Midtown — Denver, Colorado, United States
• Karmanos Cancer Institute / Wayne State University — Detroit, Michigan, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• UNC Lineberger Comprehensive Cancer Center / University of North Carolina — Chapel Hill, North Carolina, United States
• Miriam Hospital, The — Providence, Rhode Island, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Seattle Cancer Care Alliance / University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.